Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss
Analysts Agreed The S1P Receptor Modulator Should Advance
Executive Summary
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.
You may also be interested in...
Five Pivotal Trial Read-Outs To Look Out For In Early 2022
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
Sanofi/Regeneron’s Esophagitis Data Add To Dupixent’s Winning Streak
The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.
Oral Atopic Dermatitis Market Crowded, But Arena Sees Room
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.